Publications by authors named "Letitia Lensun"

Claim this Profile
P
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma.
Loretta J Nastoupil, Sattva S Neelapu, Richard Eric Davis, Felipe Samaniego, Nathan H Fowler, Letitia Lensun

Leuk Lymphoma· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional characterization of a novel somatic oncogenic mutation of .
Andrew D Whale, Lucy Colman, Letitia Lensun, Helen L Rogers, Stephen J Shuttleworth

Signal Transduct Target Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Jeffrey J Wallin, Kyle A Edgar, Jane Guan, Megan Berry, Wei Wei Prior, Letitia Lensun

Mol Cancer Ther· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.
Florence I Raynaud, Suzanne A Eccles, Sonal Patel, Sonia Alix, Gary Box, Letitia Lensun

Mol Cancer Ther· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
Adrian J Folkes, Khatereh Ahmadi, Wendy K Alderton, Sonia Alix, Stewart J Baker, Letitia Lensun

J Med Chem· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis